Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lung_CLG001_5_months_Danish_Landrace_QStarXL

ABSTRACT: biosource.anatomical.site.ontology.entry: EV:0100042 lung developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

INSTRUMENT(S): QSTAR XL

ORGANISM(S): Sus Scrofa

SUBMITTER:

PROVIDER: PAe000480 | PeptideAtlas |

REPOSITORIES: PeptideAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	PAe000480_README	Other
	PAe000480_Search_Results_9301_201507211933.properties	Other
	PAe000480_Search_Results_9301_201507211933.tar.gz	Other
	PAe000480_prot_9301_201507211933.properties	Other
	PAe000480_prot_9301_201507211933.tar.gz	Other

Items per page:

1 - 5 of 6

Similar Datasets

Lung_CLG003_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100042 lung developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000461 | PeptideAtlas

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab

Project description:Plasma from 245 patients with advanced NSCLC who received nivolumab as second-line therapy was collected and analyzed. EV-miRnome was profiled on 174/245 patients by microarray platform and selected EV-miRs were validated by qPCR. A prognostic model combining EV-miR and clinical variables was built using stepwise Cox regression analysis and tested on an independent patient cohort (71/245). EV-PD-L1 gene copy number was assessed by digital PCR. For 54 patients with disease control, EV-miR changes at best response versus baseline were investigated by microarray and validated by qPCR. EV-miRNome profiling at baseline identified two EV-miR (miR-181a-5p, miR-574-5p) that, combined with performance status, are capable of discriminating patients unlikely from those that are likely to benefit from immunotherapy (median overall survival of 4 months or higher than 9 months, respectively). EV-PD-L1 digital evaluation reported higher baseline copy number in patients at increased mortality risk, without improving the prognostic score. Best response EV-miRNome profiling selected six deregulated EV-miRs (miR19a-3p, miR-20a-5p, miR-142-3p, miR-1260a, miR-1260b, miR-5100) in responding patients. Their longitudinal monitoring highlighted a significant downmodulation already in the first treatment cycles, which lasted more than six months. Grantee: Simona Coco Grantor: Italian Ministry of Health Grant ID: CO-2016-02361470 Grant Title: Exosomal miRNA signature as prognostic marker in advanced non-small cell lung cancer (NSCLC) patients treated with Nivolumab

2024-07-28 | GSE207715 | GEO

Time trajectory analysis reveals age-modulated small RNA cargo of circulating extracellular vesicles

Project description:Previous work on murine models and humans demonstrated global as well as tissue-specific molecular ageing trajectories of RNAs. Extracellular vesicles (EVs) are membrane vesicles mediating the horizontal transfer of genetic information between different tissues. We sequenced small regulatory RNAs (sncRNAs) in two mouse plasma fractions at five time points across the lifespan from 2-18 months: (1) sncRNAs that are free-circulating (fc-RNA) and (2) sncRNAs bound outside or inside EVs (EV-RNA). Different sncRNA classes exhibit unique ageing patterns that vary between the fcRNA and EV-RNA fractions. While tRNAs showed the highest correlation with ageing in both fractions, rRNAs exhibited inverse correlation trajectories between the EV- and fc-fractions. For miRNAs, the EV-RNA fraction was exceptionally strongly associated with ageing, especially the miR-29 family in adipose tissues. Sequencing of sncRNAs and coding genes in fat tissue of an independent cohort of aged mice up to 27 months highlighted the pivotal role of miR-29a-3p and miR-29b-3p in ageing-related gene regulation that we validated in a third cohort by RT-qPCR.

2023-03-10 | GSE222857 | GEO

RNA-seq data set of EGFR mutant human non-small cell lung cancer cell lines PC9, HCC827, HCC4006 after NF2 knockout, YAP1 or WWTR1 overexpression or osimertinib treatment

Project description:Experiment was designed to study the effect of Hippo pathway on osimertinib resistance in non-small cell lung cancer cell lines. The specific comparisons investigated were: PC-9: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE, EV DMSO treated vs EV osimertinib treated HCC827: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE,EV DMSO treated vs EV osimertinib treated HCC4006: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE, EV DMSO treated vs EV osimertinib treated

2024-07-01 | E-MTAB-13831 | biostudies-arrayexpress

Liver_HEP006_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100089 liver developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000525 | PeptideAtlas

Liver_HEP011_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100089 liver developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000524 | PeptideAtlas

Liver_HEP005_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100089 liver developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000589 | PeptideAtlas

Liver_HEP003_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100089 liver developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000718 | PeptideAtlas

Heart_HRT007_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100018 Heart developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000665 | PeptideAtlas

Heart_HRT003_5_months_Danish_Landrace_QStarXL

Project description:biosource.anatomical.site.ontology.entry: EV:0100018 Heart developmental.stage.ontology.entry: EV:0300043 five months pathology.ontology.entry: EV:0400162

| PAe000512 | PeptideAtlas